Expert Providers of Cancer Patient Samples
Detecting, diagnosing and treating cancer earlier is a key aspect in decreasing cancer-related mortality. An estimated 15% of cancer-related deaths could be prevented if they were diagnosed at stage III rather than stage IV, highlighting the need for improved cancer diagnostic tests. We specialise in providing cancer serum, plasma and tissue specimens and understand the importance of annotated biological samples for your research.
Disease Staged Cancer Tissue and Biofluids
We offer a wide selection of serum and plasma markers including CA125, CA15-3, CA72-4, Cyfra21-1 and SCLC, and an extensive range of FFPE/ Frozen tissue including Breast, Colon and Liver. Our samples are accompanied by detailed documentation and ethically collected.
- Pre-treatment donor samples
- Confirmed diagnosis
- Test method and analyte concentration provided
- Bulk serum and plasma available for some markers
Prospective Collection Project Examples
mCRPC (metastatic castration-resistant prostate cancer) Plasma
Markers: PSA (Prostate-Specific Antigen)
Number of lots: 20 donors
Matrix: Liquid biopsy- Plasma in Streck tubes
Test Performed: CLIA Architect
Volume per lot: 8 ml per donor
Specification: Titre > 6.2ng/mL
Donor specifications: mCRPC progressed after Androgen Deprivation Therapy
Donor information: Date of collection, titre, treatment history & start date
Ovarian Cancer Longitudinal Plasma Collection
Markers: CA125 (Cancer Antigen 125)
Number of lots: 134 unique donors, 3 time points per donor (pre- and post-treatment + 12 month follow-up)
Matrix: K2 EDTA Plasma
Test Performed: CMIA
Volume per lot: 3-7 ml per sample
Donor specifications: Histological diagnosis of epithelial ovarian cancer. Pre-operative and/or adjuvant/neoadjuvant chemotherapy. IRB and ICF required.
Donor information: Cancer subtype and stage, Titre result, Age, Ethnicity, Treatment history, Diagnosis, Collection date. Screened negative for HIV, Hep B and C and Syphilis.
CA19-9 High Titre Remnant Sample Collection
Markers: CA19-9 (Cancer Antigen 19-9)
Number of lots: 120 donors
Matrix: Serum
Test Performed: Raybiotech CA19-9 ELISA
Volume per lot: 1 ml from each donor
Specification: Titre > 7,000 U/ml
Donor information: Date of collection, titre, collected under IRB